We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+20.7%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$108M
AUM Growth
-$52.6M
Cap. Flow
-$58.3M
Cap. Flow %
-54.02%
Top 10 Hldgs %
66.44%
Holding
50
New
11
Increased
11
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
LAB icon
Standard BioTools
LAB
+$4.55M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$2.58M
3
INCY icon
Incyte
INCY
+$2.52M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.94M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.81M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$71.4M
2
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$4.29M
3
MRUS
Merus
MRUS
+$1.93M
4
KALV
KalVista Pharmaceuticals
KALV
+$1.13M
5
OCS icon
Oculis Holding
OCS
+$989K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
1
Illumina
ILMN
$31B
$16.4M 15.17%
122,533
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.04B
$12.4M 11.47%
368,665
– –
ALPN
3
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.5M 9.69%
263,940
– –
OCS icon
4
Oculis Holding
OCS
$683M
$5.26M 4.87%
436,378
-82,555
-16% -$989K
LAB icon
5
Standard BioTools
LAB
$340M
$5.1M 4.73%
+1,883,179
New +$4.55M
EXAI
6
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$4.92M 4.56%
859,892
– –
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.06B
$4.59M 4.26%
106,680
– –
GERN icon
8
Geron
GERN
$828M
$4.37M 4.05%
1,324,550
+411,000
+45% +$921K
INCY icon
9
Incyte
INCY
$24.2B
$4.22M 3.91%
74,022
+42,000
+131% +$2.52M
MRUS
10
DELISTED
Merus
MRUS
$4.03M 3.74%
89,516
-47,522
-35% -$1.93M
ONC
11
BeOne Medicines Ltd
ONC
$32.8B
$3.6M 3.34%
23,022
+11,000
+91% +$1.77M
KALV
12
DELISTED
KalVista Pharmaceuticals
KALV
$2.6M 2.41%
219,277
-85,000
-28% -$1.13M
LBPH
13
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$2.55M 2.37%
+118,255
New +$2.58M
MIRM icon
14
Mirum Pharmaceuticals
MIRM
$6.46B
$2.41M 2.24%
96,100
– –
RYTM icon
15
Rhythm Pharmaceuticals
RYTM
$6.81B
$2.13M 1.97%
49,120
+9,050
+23% +$396K
ASND icon
16
Ascendis Pharma A/S
ASND
$16B
$2.06M 1.91%
+13,600
New +$1.94M
ACAD icon
17
Acadia Pharmaceuticals
ACAD
$4.43B
$1.9M 1.76%
102,984
+73,000
+243% +$1.81M
REPL icon
18
Replimune Group
REPL
$941M
$1.67M 1.55%
204,939
+20,200
+11% +$166K
BOLT icon
19
Bolt Biotherapeutics
BOLT
$7.67M
$1.63M 1.51%
58,348
– –
RANI icon
20
Rani Therapeutics
RANI
$87M
$1.54M 1.42%
493,584
– –
EXEL icon
21
Exelixis
EXEL
$13.3B
$1.52M 1.41%
64,200
– –
MDGL icon
22
Madrigal Pharmaceuticals
MDGL
$10.8B
$1.52M 1.41%
5,682
+4,500
+381% +$1.06M
JBIO
23
Jade Biosciences
JBIO
$1.2B
$1.42M 1.31%
1,370
– –
PACB icon
24
Pacific Biosciences
PACB
$435M
$1.03M 0.95%
274,488
– –
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$11.6B
$945K 0.88%
10,815
+7,200
+199% +$645K
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q1 2024 Portfolio in Review

As of Q1 2024, Nan Fung Group Holdings held 50 positions worth $108M, down 33% from $161M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Nan Fung Group Holdings withdrew a net $58.3M in Q1 2024, closing 5 positions and reducing 3 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $71.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Nan Fung Group Holdings opened a new position in Standard BioTools worth $5.1M.

  • Nan Fung Group Holdings's largest Q1 2024 buy was Standard BioTools: 1,883,179 shares worth $5.1M.
  • Nan Fung Group Holdings added most to Incyte in Q1 2024, an estimated $2.52M increase.
  • Nan Fung Group Holdings's biggest Q1 2024 reduction was Merus, cutting an estimated $1.93M.
  • Nan Fung Group Holdings fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $71.4M.
  • Nan Fung Group Holdings's ten largest holdings make up 66% of its $108M portfolio in Q1 2024.
  • Nan Fung Group Holdings opened 11 new positions and closed 5 in Q1 2024.
  • Nan Fung Group Holdings's portfolio value fell 33% quarter-over-quarter to $108M.

Based on Nan Fung Group Holdings's 13F filing for Q1 2024, filed 14 May 2024.